Ovagen (20 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. Because all per-administration volumes are at or under 1.5 units, use 30-unit or 50-unit insulin syringes for improved readability. Titrate slowly by adding 10 to 20 mcg every 1 to 2 weeks as tolerated.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or colder in dry, dark conditions; long-term storage at -80 °C is optimal.
• Reconstituted: refrigerate at 2 to 8 °C; use within a few days or aliquot and freeze.
• Do not store thawed solution longer than 1 to 2 days at 2 to 8 °C; avoid freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on a 16-week daily protocol with gradual titration.

Peptide Vials (Ovagen, 20 mg each):

• 16 weeks: 1 vial (with excess remaining; total usage ~13.5 mg).

Insulin Syringes (U-100, 30-unit or 50-unit recommended):

• Per week: 7 syringes (1/day).
• 16 weeks: 112 syringes (recommend ~120 with extras).

Bacteriostatic Water (10 mL bottles):

• Use 2.0 mL per vial.
• 16 weeks: 1 x 10 mL bottle.

Alcohol Swabs:

• 16 weeks: 224 swabs (3 x 100-count boxes).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes (30-unit or 50-unit preferred for low-volume accuracy); dispose in a

sharps container.

• Rotate injection sites to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Label the vial with date and time of reconstitution, diluent volume, final concentration, and initials.

How This Works

Ovagen (EDL) is an ultrashort peptide believed to enter cells and bind DNA, thereby modulating gene expression and protein synthesis. In vitro studies show EDL increases cell proliferation and alters aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures, suggesting cytoprotective effects. Such ultrashort peptides are known to influence cell differentiation, proliferation, and apoptosis via gene regulation. EDL has also been identified as an HIV-1 protease inhibitor with binding affinity in the enzyme active site.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• May support gastrointestinal and hepatic tissue bioregulation based on ultrashort peptide research.
• In vitro studies indicate potential cytoprotective effects via modulation of aging-related gene expression.
• Ultrashort peptides generally exhibit rapid metabolism and low immunogenicity.
• Side effects are not well characterized due to lack of human clinical data; mild injection-site reactions

may occur.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced diet supporting gastrointestinal and liver health.
• Maintain regular physical activity to support overall metabolic function.
• Prioritize sleep and stress management to support adherence and recovery.
• Avoid excessive alcohol and hepatotoxic substances during the protocol.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Khavinson et al. Tripeptides slow down aging process in renal cell culture (Advances in Gerontology, 2014).
2. Velazquez-Campoy A, Freire E. HIV-1 protease inhibitors Glu-Asp-Leu thermodynamic studies (Biochemistry, 2000).